Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi:10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Lo AC, Campbell BA, Pickles T, et al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood. 2020;136(8):1006–1010. doi:10.1182/blood.2019004588
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des lymphomes folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117. doi:10.1200/JCO.1997.15.3.1110
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522. doi:10.1016/S0140-6736(03)14110-4
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435. doi:10.1016/S1470-2045(14)70027-0
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi:10.1016/S0140-6736(12)61763-2
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–991. doi:10.1200/JCO.18.00605
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. - PubMed - NCBI. Blood. 2014;123(19):2944–2952. doi:10.1182/blood-2013-11-531327
   PubMed Web of Science ®Google Scholar
• Moccia AA, Taverna C, Schär S, et al. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv. 2020;4(23):5951–5957. doi:10.1182/bloodadvances.2020002858
   PubMed Web of Science ®Google Scholar
• Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947. doi:10.1056/NEJMoa1805104
   PubMed Web of Science ®Google Scholar
• Ujjani C, Wang H, Skarbnik A, et al. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. Blood Adv. 2018;2(7):762–768. doi:10.1182/bloodadvances.2017015263
   Web of Science ®Google Scholar
• Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–e182. doi:10.1016/S2352-3026(17)30028-5
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. J Clin Oncol. 2018;36(22):2259–2266. doi:10.1200/JCO.2017.76.3656
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–2833. doi:10.1200/JCO.1998.16.8.2825
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416–4423. doi:10.1182/blood-2003-10-3411
   PubMed Web of Science ®Google Scholar
• Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635–3640. doi:10.1200/JCO.2014.59.9258
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a Phase III Study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. doi:10.1200/JCO.19.00010
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012;23(9):2356–2362. doi:10.1093/annonc/mdr620
   PubMed Web of Science ®Google Scholar
• Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013;119(21):3797–3804. doi:10.1002/cncr.28299
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Hess G, et al. A Phase IIa, Open-Label, Multicenter Study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-hodgkin’s lymphoma: long-term follow-up, final analysis. Blood. 2019;134(Supplement_1):4078. doi:10.1182/blood-2019-124297
   Web of Science ®Google Scholar
• A Phase 3 Study to assess efficacy and safety of tafasitamab plus lenalidomide and rituximab compared to placebo plus lenalidomide and rituximab in patients with Relapsed/Refractory (R/R) follicular Lymphoma or Marginal Zone Lymphoma. (InMIND). Available from: https://clinicaltrials.gov/ct2/show/NCT04680052?term=NCT04680052&draw=2&rank=1. Accessed July 14, 2021.
   Google Scholar
• Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–e265. doi:10.1016/S2352-3026(19)30026-2
   PubMed Web of Science ®Google Scholar
• Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-hodgkin lymphoma: preliminary safety and clinical activity of a Phase Ib/II Study. Blood. 2016;128(22):622. doi:10.1182/blood.V128.22.622.622
   Web of Science ®Google Scholar
• Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. J Clin Oncol. 2018;36(15_suppl):7507. doi:10.1200/JCO.2018.36.15_suppl.7507
   Web of Science ®Google Scholar
• Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a Phase 1 Study of loncastuximab tesirine in relapsed/refractory B-cell non-hodgkin lymphoma. Blood. 2021;137(19):2634–2645.
   PubMed Web of Science ®Google Scholar
• Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251–262. doi:10.1038/nrc1589
   PubMed Web of Science ®Google Scholar
• Pongas G, Cheson BD. PI3K signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol. 2016;43(6):647–654. doi:10.1053/j.seminoncol.2016.11.011
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018. doi:10.1056/NEJMoa1314583
   PubMed Web of Science ®Google Scholar
• Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156–e159. doi:10.3324/haematol.2016.151738
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Schuster SJ, deVos S, et al. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leuk Lymphoma. 2021;62(5):1077–1087.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Speed bumps on the road to a chemotherapy-free world for lymphoma patients. Blood. 2016;128(3):325–330. doi:10.1182/blood-2016-04-709477
   Web of Science ®Google Scholar
• Barr PM, Saylors GB, Spurgeon SE, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 2016;127(20):2411–2415. doi:10.1182/blood-2015-12-683516
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher B, Jung S-H, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood. 2014;124(21):3091. doi:10.1182/blood.V124.21.3091.3091
   Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II Study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–922. doi:10.1200/JCO.18.00915
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905. doi:10.1200/JCO.2017.75.4648
   PubMed Web of Science ®Google Scholar
• Chauhan AF, Cheson BD. Copanlisib in the treatment of relapsed follicular lymphoma: utility and experience from the clinic. Cancer Manag Res. 2021;13:677–692. doi:10.2147/CMAR.S201024
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678–689.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Gorbatchevsky I, Hiemeyer F, Cupit L, Childs BH. Abstract CT212: CHRONOS-2: a randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL). Cancer Res. 2015;75(15Supplement):CT212–CT212.
   Web of Science ®Google Scholar
• Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kdelta/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39:JCO2003433.
   Web of Science ®Google Scholar
• Maharaj K, Powers JJ, Achille A, et al. The dual PI3Kdelta/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020;4(13):3072–3084. doi:10.1182/bloodadvances.2020001800
   PubMed Web of Science ®Google Scholar
• Lynch RC, Paneesha S, Avigdor A, et al. Phase 2 Study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma (CITADEL-203). Blood. 2020;136(Supplement 1):36–37. doi:10.1182/blood-2020-134869
   Web of Science ®Google Scholar
• Zelenetz AD, Zinzani PLL, Chan H, et al. ME-401-003 (TIDAL): a multicenter, randomized, double-blind, placebo-controlled, two-arm, Phase 2 Study of ME-401 investigating continuous and intermittent dosing schedules in patients with relapsed/refractory follicular lymphoma. Blood. 2019;134(Supplement_1):5244. doi:10.1182/blood-2019-124326
   Web of Science ®Google Scholar
• Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, Phase II DAWN Study. J Clin Oncol. 2018;36(23):2405–2412. doi:10.1200/JCO.2017.76.8853
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182–190. doi:10.1182/blood-2017-09-804641
   PubMed Web of Science ®Google Scholar
• Fowler NH, Trotman J, Auer R, et al. Randomized Phase 2 zanubrutinib (BGB-3111) + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL). Blood. 2019;134(Supplement_1):5252. doi:10.1182/blood-2019-122628
   Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-Human Study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833. doi:10.1200/JCO.2016.70.4320
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964–1976. doi:10.1182/blood-2018-11-880526
   PubMed Web of Science ®Google Scholar
• de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–1938. doi:10.1093/annonc/mdy256
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Flinn IW, Yuen SLS, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628–2637.
   Web of Science ®Google Scholar
• Ujjani CS, Lai C, Leslie LA, et al. Ibrutinib and venetoclax in relapsed and refractory follicular lymphoma. Blood. 2020;136(Supplement 1):46–47. doi:10.1182/blood-2020-136219
   Web of Science ®Google Scholar
• Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–692. doi:10.1016/j.ccr.2013.04.011
   PubMed Web of Science ®Google Scholar
• Bodor C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165–3168. doi:10.1182/blood-2013-04-496893
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–1442. doi:10.1016/S1470-2045(20)30441-1
   PubMed Web of Science ®Google Scholar
• FDA Adminstration. Available from: https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma. Accessed July 14, 2021.
   Google Scholar
• Patel K, Bailey N, Pagel JM. A phase 2, Open-Label, Multicenter Study of tazemetostat in combination with rituximab for the treatment of relapsed or refractory follicular lymphoma. Blood. 2020;136(Supplement 1):4. doi:10.1182/blood-2020-136653
   Web of Science ®Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42–43. doi:10.1182/blood-2020-136659
   Web of Science ®Google Scholar
• Bannerji R, Arnason JE, Advani R, et al. Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and other B-Cell Non-Hodgkin Lymphoma (B-NHL) subtypes. Blood. 2018;132(Supplement 1):1690. doi:10.1182/blood-2018-99-113328
   Web of Science ®Google Scholar
• Kim TM, Alonso A, Prince M, et al. A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-hodgkin lymphoma. Blood. 2020;136(Supplement 1):28–29. doi:10.1182/blood-2020-136344
   Web of Science ®Google Scholar
• Assouline SE, Kim WS, Sehn LH, et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(Supplement 1):42–44. doi:10.1182/blood-2020-135839
   Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Blood. 2020;136(Supplement 1):45–46. doi:10.1182/blood-2020-133820
   Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;JCO:20.03175.
   Google Scholar
• Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of zuma-5: a phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood. 2020;136(Supplement 1):40–41.
   Google Scholar
• Chavez JC, Jacobson CA, Sehgal AR, et al. Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed/refractory indolent non-hodgkin lymphoma in ZUMA-5. Blood. 2020;136(Supplement 1):34. doi:10.1182/blood-2020-135871
   Web of Science ®Google Scholar
• Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019;134(7):636–640. doi:10.1182/blood.2019000905
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225–232. doi:10.1016/j.coi.2012.01.010
   PubMed Web of Science ®Google Scholar
• Tsai RK, Discher DE. Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180(5):989–1003. doi:10.1083/jcb.200708043
   PubMed Web of Science ®Google Scholar
• Campbell IG, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res. 1992;52(19):5416–5420.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–1721. doi:10.1056/NEJMoa1807315
   PubMed Web of Science ®Google Scholar
• Patel K, Ramchandren R, Maris M, et al. Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the Ongoing First-in-Human Dose Escalation Study. Blood. 2020;136(Supplement 1):46–47. doi:10.1182/blood-2020-136607
   Web of Science ®Google Scholar
• Kim TM, Lakhani N, Gainor J, et al. ALX148, a CD47 blocker, in combination with rituximab in patients with non-hodgkin lymphoma. Blood. 2020;136(Supplement 1):13–14. doi:10.1182/blood-2020-135941
   Web of Science ®Google Scholar
• Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637–645. doi:10.1182/blood.2019004753
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib Study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.9789
   PubMed Web of Science ®Google Scholar